The United States has grow to be a hotbed for groundbreaking cannabis education. As legalization’s taken off like wildfire, conferences intent on satiating the industry’s thirst for know-how are becoming held across the nation. But with so a lot of diverse sector meetings to select from, deciding which a single to attend can be overwhelming.
Having said that, not all cannabis conferences are homogeneous. Lots of gatherings have a powerful B2B concentrate made to bring corporations collectively whilst focusing on the science and innovations of the field. But most spot the majority of their emphasis on the seed-to-sale elements of the sector. CannMed, on the other hand, has a broader goal that keeps patient care in thoughts — an aspect of the space that is gradually fading due to corporate revenue — and as an alternative focuses on possessing a seed-to-bedside mentality.
Kevin McKernan of Medicinal Genomics (Courtesy of CannMed)
Not Your Typical Cannabis Conference
That mindset brings collectively researchers, physicians, sufferers, entrepreneurs, and other individuals in a format that fosters education and collaboration in the pursuit of innovation. The 4 principal concentrate regions of the conference are science, cultivation, lab security, and medicine, which means that the occasion delivers important information and facts and possibilities to a broad pool of sector people.
“Anyone who’s involved in genetics, analytical chemistry, and the healthcare application of cannabis can advantage from this occasion,” stated Kevin McKernan, the chief science officer of Medicinal Genomics and founder of CannMed.
McKernan told MERRY JANE that CannMed is also diverse simply because corporations can not acquire their way into presenting at the occasion.
“It really is not a spend to play conference,” he stated in a phone interview. “It’s a single exactly where persons submit abstracts and an independent committee ends up reviewing these and picking them for speaking positions or poster presentations.”
Elan Sudberg, the CEO of analytical laboratory Alkemist Labs, stated that his corporation will be sending representatives to CannMed, which includes a single who will be moderating a panel at the conference. He also agrees that not all cannabis events share the exact same ideology.
“There are so a lot of conferences surrounding this speedily expanding sector, not all of them are worth the time and revenue to attend,” stated Sudberg in an e-mail to MERRY JANE. “CannMed brings a level of professionality and maturity which is sorely necessary. As a testing lab priming to enter the legal cannabis testing market place, conferences like CannMed are vital to our path.”
Sudberg noted that he expects the emerging “vape lung” illnesses — and fatalities — will be on the minds of a lot of in attendance. He predicts the controversy could lead to a shakeup of the concentrates sector of the cannabis sector.
“With a barrier of entry so low and the earnings higher, it is been my suspicion that the largely unregulated vaping sector will come crashing down when the possible overall health implications begin to pile up,” he stated.
Sudberg also noted that even healthcare marijuana sufferers searching for information and facts will uncover CannMed a important mastering practical experience.
“Today, sufferers have additional possibilities than only illegal drugs or mainstream pharmaceuticals,” he stated. “They rely on the possible medicinal properties of cannabis as either an adjunct to or replacement for regular western medicine’s options. Conferences like CannMed assistance to unlock these plant secrets and bring them a single step closer to the medicine cabinet of the future.”
Dr. Raphael Mechoulam (Courtesy of CannMed)
‘Father of Cannabis Research’ to Speak at CannMed
A highlight of this year’s CannMed conference is positive to be a presentation by Dr. Raphael Mechoulam, a professor of medicinal chemistry at the Hebrew University of Jerusalem and the head of study at EPM, a US developer of cannabinoids. Regarded as the “father of cannabis study,” Mechoulam found the human endocannabinoid program in the 1960s and has continued to study it and complementary phytocannabinoids for additional than 60 years. He will provide a keynote address at CannMed, which this year will function additional than 50 speakers and presentations.
“As often, we are honored to have Professor Mechoulam with us, but especially so this year. Ever due to the fact assisting us make CannMed and as a member of our Advisory Board, he has been generous with his time and his invaluable insights,” stated Brendan McKernan, the CEO of Medicinal Genomics, a leader in cannabis security testing, cannabis genetics, and point-of-develop testing options in a press release. “And he is a single of the causes so a lot of of the greatest minds in cannabis select to share their perform at CannMed. This is precisely the conference’s purpose for becoming.”
Through his presentation at CannMed, Mechoulam is anticipated to reveal the science and chemistry behind his most up-to-date innovation, a new family members of steady cannabinoid acid molecules that might offer you promising therapeutic effects and greater potency than current cannabinoids.
“Every single year for the previous 4 years, we have looked forward to advancing our understanding of what cannabis is capable of,” added Brendan McKernan, who is Kevin’s brother. “This year, we count on to make a quantum leap in that understanding.”
Gallery — Your Botanical Guide to the Components of the Cannabis Plant
Mechoulam told MERRY JANE in an e-mail that steady acid types of cannabinoids present new possibilities for researchers.
“The accurate all-natural compounds from the plant are cannabinoids acids, for instance, THC acid [THC-A] and cannabidiol acid [CBD-A],” Mechoulam stated. “Even although we synthesized them in the lab a lot of years ago, we by no means tested them simply because these compounds are not steady. The acids break down effortlessly and so only minor research had been produced.”
But with a steady kind of these cannabinoid acids, researchers will be in a position to pursue the possible therapeutic effects of these distinct molecules.
“In the final years, we began pondering that perhaps these acids are essential, so we had been in a position to stabilize, analyze, and recognize the activity of these compounds,” Mechoulam stated. “We located out that cannabidiol acid is additional potent than cannabidiol itself. The possibilities are that gradually and to a particular extent, cannabidiol acid will prove to be parallel to cannabidiol oil in its activity simply because in a lot of elements, it is a great deal additional active.”
Other subjects on the docket for discussion at CannMed 2019 will include things like the synthesis of cannabinoids with yeasts and making use of genomics and breeding to enhance cannabis cultivation yields, amongst other individuals.
The conference will be held on September 23rd and 24th at the Pasadena Convention Center, and is presented by Medicinal Genomics in partnership with EPM. You can acquire tickets for this month’s occasion at right here. And you can use “MERRYJANEsave15” to get 15 % off your buy.
Stick to AJ on Instagram and Facebook
Stick to CannMed on Facebook and Twitter